Onkos Surgical has secured a Series A financing and partnered with MicroPort Orthopedics. The financial details were undisclosed in the company's announcement, but an SEC filing reveals that Onkos recently secured the first $6.1 million of a financing that's expected to total $15.3 million.
Procyrion is developing what it says is the first catheter-deployed micropump for the heart and has nabbed a $10 million Series B round to back clinical development.
Merck's Keytruda is two-for-two with the U.K.'s cost watchdog, nabbing another thumbs-up to treat skin cancer days after the National Institute of Health and Care Excellence signed off on the med for patients who have already received treatment.
The Wyss Institute for Biologically Inspired Engineering at Harvard University has launched startup Opsonix to develop its pathogen-extracting, extracorporeal sepsis device. Hansjörg Wyss, who founded the Institute with a $125 million gift in 2008, also participated in an $8 million Series A round that was led by Baxter Ventures.
Singapore-based TauRx Pharmaceuticals has pulled in $135 million in a fundraising program launched in March, setting the stage for ongoing Phase III trials for a unique Alzheimer's candidate focused on inhibiting the aggregation of tau tangles in the brain.
GE Ventures is dialing up its partnership with global health company StartUp Health, expanding a program that invests in and coaches promising healthcare startups to help them gain footing in the field.
Specialty pharma OptiNose hopes to use up to $30 million in new financing to get its OPN-375 in combination with its novel breath-powered device through the FDA. But the agency already demonstrated some skepticism around the device last year--it issued a complete response letter to OptiNose partner Avanir because of device errors and required further testing.
Merck's Keytruda got a green light from the U.K.'s cost-effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as it picks up steam in its head-to-head battle with Bristol-Myers Squibb's Opdivo.
Wisconsin devicemaker Stratatech scored a $247 million contract with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to develop its skin replacement product for severe burns, giving the company a boost as it chases FDA approval for its product.
The typical approach to achieving consistent and high-quality vascular access for chronic kidney disease patients in need of dialysis is to surgically construct an arteriovenous (AV) fistula, creating a direct connection between an artery and a vein in the arm. Startup TVA Medical has a minimally invasive, catheter-based that can achieve the same goal--only without surgery.